Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a strong performance in Q2 2025, surpassing expectations in both revenue and earnings, while also increasing full-year guidance, indicating robust operational health. The company experienced a significant 60% quarter-over-quarter sales growth for Mounjaro in international markets, bolstered by new product launches in regions such as Brazil, Mexico, and India. Moreover, the anticipated introduction of orforglipron presents a compelling addition to the GLP-1 market, enhancing Eli Lilly's portfolio with an oral weight loss option that aligns with patient preferences.

Bears say

The financial outlook for Eli Lilly is negatively impacted by several key risks, including potential pricing pressures and a subpar prescription trajectory for tirzepatide, which may not meet performance expectations. Additionally, the company has identified a decline in Zepbound prescriptions, which is anticipated to hinder volumetric growth in the upcoming quarter. Furthermore, heightened competition from drugs such as orforglipron poses a significant threat to Lilly's market share, as it is expected to disrupt existing revenue streams, particularly in the cardiometabolic segment.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,099.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,099.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.